Cormedix Stock Performance
| CRMD Stock | USD 7.69 0.34 4.63% |
The firm shows a Beta (market volatility) of -0.0837, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CorMedix are expected to decrease at a much lower rate. During the bear market, CorMedix is likely to outperform the market. At this point, CorMedix has a negative expected return of -0.48%. Please make sure to confirm CorMedix's kurtosis, and the relationship between the value at risk and rate of daily change , to decide if CorMedix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CorMedix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.43) | Five Day Return (2.45) | Year To Date Return (37.66) | Ten Year Return (3.44) | All Time Return (49.47) |
Last Split Factor 1:5 | Dividend Date 2019-03-26 | Last Split Date 2019-03-26 |
1 | SNY Stock Down on Double Trouble With Multiple Sclerosis Drug | 12/16/2025 |
2 | FDA Issues CRL to SNYs Regulatory Filing for Multiple Sclerosis Drug | 12/24/2025 |
3 | CorMedix Therapeutics appoints Mike Seckler as chief commercial officer | 01/08/2026 |
4 | CorMedix Valuation After New Leadership Moves And 2026 Revenue Guidance | 01/13/2026 |
5 | Will DefenCath Continue to Aid CorMedixs Top Line in Q4 Earnings | 01/15/2026 |
6 | Disposition of 29585 shares by Todisco Joseph of CorMedix at 3.38 subject to Rule 16b-3 | 01/16/2026 |
7 | Is CorMedix Offering An Opportunity After Its Recent 43 percent Share Price Slide | 01/20/2026 |
8 | Disposition of 10000 shares by Dillione Janet of CorMedix at 6.88 subject to Rule 16b-3 | 01/21/2026 |
9 | Acquisition by Stewart Robert A of 30453 shares of CorMedix subject to Rule 16b-3 | 01/26/2026 |
10 | CorMedix Valuation Check After Recent Share Price Pullback And Melinta Acquisition Outlook | 01/27/2026 |
11 | CRMD Down 31 percent in a Month Is This an Indication to Sell the Stock - TradingView | 01/30/2026 |
12 | Acquisition by Todisco Joseph of 77156 shares of CorMedix subject to Rule 16b-3 | 02/04/2026 |
| Begin Period Cash Flow | 43.8 M | |
| Total Cashflows From Investing Activities | 21.2 M | |
| Free Cash Flow | -50.7 M |
CorMedix Relative Risk vs. Return Landscape
If you would invest 1,142 in CorMedix on November 12, 2025 and sell it today you would lose (373.00) from holding CorMedix or give up 32.66% of portfolio value over 90 days. CorMedix is currently does not generate positive expected returns and assumes 5.5199% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than CorMedix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CorMedix Target Price Odds to finish over Current Price
The tendency of CorMedix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.69 | 90 days | 7.69 | about 88.66 |
Based on a normal probability distribution, the odds of CorMedix to move above the current price in 90 days from now is about 88.66 (This CorMedix probability density function shows the probability of CorMedix Stock to fall within a particular range of prices over 90 days) .
CorMedix Price Density |
| Price |
Predictive Modules for CorMedix
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CorMedix. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.CorMedix Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. CorMedix is not an exception. The market had few large corrections towards the CorMedix's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CorMedix, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CorMedix within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.45 | |
β | Beta against Dow Jones | -0.08 | |
σ | Overall volatility | 1.87 | |
Ir | Information ratio | -0.1 |
CorMedix Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CorMedix for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CorMedix can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CorMedix generated a negative expected return over the last 90 days | |
| CorMedix has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 43.47 M. Net Loss for the year was (17.93 M) with profit before overhead, payroll, taxes, and interest of 202.1 M. | |
| CorMedix currently holds about 64.62 M in cash with (50.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Todisco Joseph of 77156 shares of CorMedix subject to Rule 16b-3 |
CorMedix Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CorMedix Stock often depends not only on the future outlook of the current and potential CorMedix's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CorMedix's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 58.9 M | |
| Cash And Short Term Investments | 51.7 M |
CorMedix Fundamentals Growth
CorMedix Stock prices reflect investors' perceptions of the future prospects and financial health of CorMedix, and CorMedix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CorMedix Stock performance.
| Return On Equity | 0.75 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.76 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 697.91 M | ||||
| Shares Outstanding | 78.79 M | ||||
| Price To Earning | (0.88) X | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 2.83 X | ||||
| Revenue | 43.47 M | ||||
| Gross Profit | 202.1 M | ||||
| EBITDA | (18.98 M) | ||||
| Net Income | (17.93 M) | ||||
| Cash And Equivalents | 64.62 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 517.01 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 4.78 X | ||||
| Cash Flow From Operations | (50.61 M) | ||||
| Earnings Per Share | 2.21 X | ||||
| Market Capitalization | 605.89 M | ||||
| Total Asset | 118.85 M | ||||
| Retained Earnings | (339.63 M) | ||||
| Working Capital | 80.74 M | ||||
| Current Asset | 37.06 M | ||||
| Current Liabilities | 3.06 M | ||||
About CorMedix Performance
By analyzing CorMedix's fundamental ratios, stakeholders can gain valuable insights into CorMedix's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CorMedix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CorMedix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 782.45 | 625.86 | |
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.15) | (0.14) | |
| Return On Equity | (0.24) | (0.26) |
Things to note about CorMedix performance evaluation
Checking the ongoing alerts about CorMedix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CorMedix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CorMedix generated a negative expected return over the last 90 days | |
| CorMedix has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 43.47 M. Net Loss for the year was (17.93 M) with profit before overhead, payroll, taxes, and interest of 202.1 M. | |
| CorMedix currently holds about 64.62 M in cash with (50.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Todisco Joseph of 77156 shares of CorMedix subject to Rule 16b-3 |
- Analyzing CorMedix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CorMedix's stock is overvalued or undervalued compared to its peers.
- Examining CorMedix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CorMedix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CorMedix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CorMedix's stock. These opinions can provide insight into CorMedix's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CorMedix Stock analysis
When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |